Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy

Annals of Medicine

Volumn 28, Issue 2, 1996, Pages 175-182

  Hoekman, Klaas ^a   Vermorken, Jan B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemoprotection; Haematopoietic growth factors (HGFs); High dose chemotherapy (HDC); Nonhaematological toxicity (NHTOX); Peripheral blood stem cell transfusion (PBSCT)

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CEFTAZIDIME; CHLORHEXIDINE; CIPROFLOXACIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; GRANISETRON; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; IMIPENEM; MELPHALAN; MITOXANTRONE; ONDANSETRON; RAZOXANE; THIOTEPA; TISSUE PLASMINOGEN ACTIVATOR; TROPISETRON;

BLADDER DISEASE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CATHETERIZATION; CLINICAL TRIAL; FEVER; HEART FAILURE; HEMATOPOIETIC STEM CELL; HEMORRHAGIC CYSTITIS; HUMAN; INTESTINE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER TOXICITY; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL BLOOD STEM CELL; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SOLID TUMOR; STEM CELL TRANSPLANTATION; VOMITING;

EID: 0029921382     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899609092943     Document Type: Review

References (66)

1. Frei E. Pharmacologic strategies for high dose chemotherapy. In: Armitage JC, Antman KH eds, High-dose Chemotherapy. Baltimore: Williams & Witkins, 1992: 3-13.
2. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43.
3. Ayash LJ, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
4. van der Wall E, Nooijen WJ, Baars JW, et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995; 71: 857-62.
5. Antman KH, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-10.
6. Patrone F, Ballestrero A, Ferrando F, et al. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 1995; 13: 840-6.
7. Fennelly D, Schneider J, Spriggs D, et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced oavarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995; 13: 1160-6.
8. Leyvraz S, Kettere N, Perey L, et al. Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor. Br J Cancer 1995; 72: 178-82.
9. van der Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy regimens for solid tumours. Cancer Treat Rev 1995; 21: 105-32.
10. Fields KK, Elfenbein GJ, Lazarus HM, et al. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995; 13: 323-32.
11. Pittman KB, To LB, Bayly JL, et al. Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer. Bone Marrow Transpl 1992; 10: 535-40.
12. Rodenhuis S, Baars JW, Schornagel JH, van der Wall E, Holtkamp M, Nooijen WJ. Multiple courses of high-dose cyclophosphamide, thiotepa and carboplatin (CTC) with autologous stem cell support. Proc Am Soc Clin Oncol 1995; Abstract 914.
13. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13: 1036-43.
14. Navari RM, Province WS, Perrine GM, Kilgore JR. Comparison of intermittent ondansetron vs. continuous infusion of metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer 1993; 72: 583-6.
15. Navari RM, Gandara D, Heskett P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 133: 1242-8.
16. Jantunen IT, Muhonen TT, Kataja W, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomized study. Eur J Cancer 1993; 29 a: 1669-72.
17. Hesketh PJ, Beck T, Uhlenhopp M, et al. Adjusting the dose of intravenous ondansetron plus dexamethason to the emetogenic potential of the chemotherapy regimen. J Clin Oncol 1995; 13: 2117-22.
18. Grunberg SM, Lane M, Lester EP, et al. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 1993; 32: 268-72.
19. Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050-7.
20. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600.
21. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
22. Murgia L, Zamkopff K. Effective control of nausea and vomiting using infusional perphenazine in patients with breast cancer undergoing high dose chemotherapy with cyclophosphamide, thiotepa, carboplatin (CTCb) followed by peripheral blood stem cell transplant. Proc Am Soc Clin Oncol 1995; Abstract 971.
23. Lew MA, Kehoe K, Ritz J, et al. Ciprofloxacin vs. trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients:, a randomized, controlled trial. J Clin Oncol 1995; 13: 239-50.
24. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381-96.
25. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime vs. imipenem. J Clin Oncol 1995; 13: 165-76.
26. Maschmeyer G, Link H, Hiddemann W, et al. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994; 73: 2296-304.
27. Levine SJ. An approach to the diagnosis of pulmonary infections in immunosuppressed patients. Semin Respir Infect 1992; 7: 81-95.
28. Swerdloff JN, Filler SG, Edwards JE. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993; 17: S457-67.
29. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19: 529-42.
30. Rubin P, Petros W, Vredenbirgh J, et al. Cyclophosphamide-induced cardiomyopathy following high-dose chemotherapy. Proc Am Soc Clin Oncol 1995; Abstract 968.
31. Herman EH, Witiak DT, Hellman K, Waravdekar VS. Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. Adv Pharmacol Chemother 1982; 19: 249-90.
32. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992: 10: 117-27.
33. van Acker SABE, Voest EE, Beems RB, et al. Cardioprotective properties of O-(b-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. Cancer Res 1993; 53: 4603-7.
34. Dorr RT, Lagel KE. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro. Proc Am Soc Clin Oncol 1994; Abstract 1495.
35. Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640-7.
36. Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993; 147: 1264-70.
37. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592-8.
38. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-36.
39. Bearman SI, Shuart MC, Hinds MS, et al. Recombinant human tissue plasminogen activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-62.
40. Kemp GM. Amifostine selectively protects against acute and cumulative hematologic and renal toxicities of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. In: Bonte J, Maggino T, eds. Advances on Gynaecological Oncology. Rome: CIC Edizioni Intern, 1995: 197-201.
41. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs 1995; 6: 369-83.
42. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994; 331: 1735-9.
43. Haire WD, Lieberman RP, Edney J, et al. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990; 66: 900-8.
44. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233-8.
45. Raad II, Luna M, Khalil SAM, et al. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271: 1014-6.
46. Hjermstad MJ, Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation - a review of the literature. Eur J Cancer 1994; 31a: 163-73.
47. Andrykowski MA, Greiner CB, Altmaier EM, et al. Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer 1995; 71: 1322-9.
48. Barton C, Waxman J. Effects of chemotherapy on fertility. Blood Rev 1990; 4: 187-95.
49. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol 1993; 11: 415-24.
50. Doria R, Holford T, Farber LR, Prosnitz LR, Cooper DL. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995; 13: 2016-22.
51. Ronatiner A. Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation. J Clin Oncol 1994; 12: 2521-3.
52. Tallman MS, Gray R, Bennet JM, et al. Leucogemic potential of adjuvant chemotherapy for early stage breast cancer: The Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13: 1557-63.
53. Crews JR, Vredenburgh J, Bigner S, et al. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after high-dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT). Proc Am Soc Clin Oncol 1995; Abstract 935.
54. Schuchter LM, Luginbuhl WE, Meropol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992; 19: 742-51.
55. Glover DJ, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase Il trial. J Clin Oncol 1986; 4: 584-8.
56. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993; 72: 2495-501.
57. Treskes M, Boven E, van de Loosdrecht AA, et al. Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 1994; 30 a: 183-7.
58. Treskes M, Boven E, Holwerda U, et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 1992; 52: 2257-60.
59. Milas L, Hunter NR, Stephens LC, Petus LJ. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropyl-amino)-ethylphosphorothioic acid. Cancer Res 1984; 44: 5567-9.
60. Shpall EJ, Stemmer SM, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132-7.
61. Patchen ML, MacVittie TJ. Granulocyte colony-stimulating factor and amifostine (ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 1994; 21: 26-32.
62. Ayash U, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-9.
63. Rahman Z, Frye D, Buzdar A, Hortobagyi G. A retrospective analysis to evaluate the selection process for high-dose chemotherapy (HDC) on the outcome of patients (PT) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1995; Abstract 78.
64. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-9.
65. Lazo JS. Endothelial injury caused by antineoplastic agents. Biochem Pharmacol 1986; 35: 1919-23.
66. Smyth J, Bowman A, Perren T, et al. Glutathione improves the therapeutic index of cisplatin and quality of life for patients with ovarian cancer. Proc Am Soc Clin Oncol 1995; Abstract 761.